Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
Supported by

Controversial Reimbursement Pulled From Pharma Senate Bill

Major pharmaceutical legislation could be facing big changes today in the Nevada legislature, but there's debate over what exactly will change..

Senate Bill 265 is a pharmaceutical omnibus bill, which, among other things, seeks to put price controls on certain diabetes medication. 

That provision, though, is out as lawmakers seek to amend the bill ahead of a committee vote Wednesday. 

Sponsor Message

That’s according to the bill’s sponsor, Las Vegas Democratic Senator Yvanna Cancela.

She says the language is being removed to advance the bill. 

The move to amend SB 265 comes after a memo from the legislature's litigation counsel Monday raised concerns over a likely legal challenge concerning the Commerce Clause of the U.S. constitution.

Back in 2006 the U.S. Supreme Court struck down a Washington, D.C. law that tried to implement similar price controls on prescription drugs.